Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04623775 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 468 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT04702880 | A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | completed | Phase 2 | 135 | Bristol-Myers SquibbINDUSTRY | 11 |
| Jun 17, 2026 |
| clinicaltrials |
| NCT00453154 | Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 156 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04181788 | Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies | completed | Phase 1 / Phase 2 | 155 | PfizerINDUSTRY | 6 | Jun 15, 2026 | clinicaltrials |
| NCT04262856 | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer(ARC-7) | completed | Phase 2 | 151 | Arcus Biosciences, Inc.INDUSTRY | 7 | Jun 15, 2026 | clinicaltrials |
| NCT04205552 | Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients(NEOpredict) | completed | Phase 2 | 90 | University Hospital, EssenOTHER | 3 | Jun 11, 2026 | clinicaltrials |
| NCT05215067 | A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 44 | AkesoINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03516981 | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | completed | Phase 2 | 245 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT04258033 | A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)(KUNPENG) | completed | Phase 2 | 145 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04619797 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(SKYSCRAPER-06) | completed | Phase 2 / Phase 3 | 542 | Hoffmann-La RocheINDUSTRY | 21 | Jun 3, 2026 | clinicaltrials |
| NCT05546476 | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15(PROACC-1) | completed | Phase 2 | 187 | PfizerINDUSTRY | 11 | Jun 3, 2026 | clinicaltrials |
| NCT05420220 | Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 95 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT02438722 | S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 174 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT02444741 | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 124 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03735095 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03758287 | Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative | completed | Phase 1 / Phase 2 | 108 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT04010357 | Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04042558 | A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies(GFPC 06-2018) | completed | Phase 2 | 150 | Centre Francois BaclesseOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT02314481 | Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity(DARWINII) | completed | Phase 2 | 50 | University College, LondonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03563716 | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 135 | Genentech, Inc.INDUSTRY | 6 | May 4, 2026 | clinicaltrials |
| NCT05865990 | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease(TUXEDO-3) | completed | Phase 2 | 63 | MedSIROTHER | 2 | May 4, 2026 | clinicaltrials |
| NCT01625234 | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 131 | Xcovery Holdings, Inc.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02664935 | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | completed | Phase 2 | 423 | University of BirminghamOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02839265 | FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer(FLT3) | completed | Phase 2 | 33 | Montefiore Medical CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03481114 | Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer(REPAINT) | completed | Phase 2 | 55 | Albert Einstein College of MedicineOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01802632 | AZD9291 First Time In Patients Ascending Dose Study(AURA) | completed | Phase 1 / Phase 2 | 603 | AstraZenecaINDUSTRY | 10 | Apr 20, 2026 | clinicaltrials |
| NCT05519865 | A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC | completed | Phase 2 | 118 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03634241 | Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study | completed | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03446547 | Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)(ASTEROID) | completed | Phase 2 | 106 | Vastra Gotaland RegionOTHER_GOV | 3 | Apr 14, 2026 | clinicaltrials |
| NCT03523702 | The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial(SPRINT) | completed | Phase 2 | 25 | Montefiore Medical CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04660097 | Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer | completed | Phase 2 | 34 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02087423 | A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer(ATLANTIC) | completed | Phase 2 | 446 | AstraZenecaINDUSTRY | 18 | Apr 6, 2026 | clinicaltrials |
| NCT03158129 | Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | completed | Phase 2 | 101 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03589547 | Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung(358) | completed | Phase 2 | 11 | Brown UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04677595 | Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-C) | completed | Phase 2 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04351256 | Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy(TRADE-hypo) | completed | Phase 2 | 51 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03915951 | An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | completed | Phase 2 | 98 | PfizerINDUSTRY | 5 | Mar 24, 2026 | clinicaltrials |
| NCT04484142 | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | completed | Phase 2 | 137 | Daiichi SankyoINDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT02818920 | Neoadjuvant Pembrolizumab(TOP 1501) | completed | Phase 2 | 35 | Neal Ready MD PhDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03313804 | Priming Immunotherapy in Advanced Disease With Radiation | completed | Phase 2 | 76 | John L. Villano, MD, PhDOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03083041 | A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 210 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04900363 | A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC | completed | Phase 1 / Phase 2 | 108 | AkesoINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05263947 | Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation | completed | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02523469 | ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 67 | Medical University of South CarolinaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04184921 | Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients | completed | Phase 2 | 216 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05429320 | A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT01897480 | A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations(Balise) | completed | Phase 2 | 168 | Eli Lilly and CompanyINDUSTRY | 9 | Jan 26, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 18, 2026source: clinicaltrials